Our Pipeline

Status: Status: CLIA Certificate of Compliance (COC) Acquired

ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) when it is a concern in children aged 1 month up to 36 months of age. It detects a biomarker associated with autism using a strand of hair. The test is performed by the LinusBio CLIA-certified laboratory (CLIA #31d2307499). 

Status: In development

StrandDx is the first molecular autism spectrum disorder (ASD) diagnostic biomarker. The test has received FDA Breakthrough designation. 

Status: Enrollment ongoing

Attention Deficit Hyperactive Disorder reduces people’s ability to focus, makes them more active and impulsive and is usually diagnosed through interviews and psychological tests. LinusBio’s diagnostic would be the first molecular test for ADHD, providing objective measures to aid in diagnosing patients and testing new therapies in clinical trials.

Status: Enrollment ongoing

Psychosis and schizophrenia can cause delusions, hallucinations, and other behavioral issues. There are effective therapies in the clinic, but the first step is diagnosis. At this moment, there are no molecular diagnostics for these conditions. 

Status: FDA discussion initiated

Amyotrophic lateral sclerosis destroys the neurons that control muscle movement. As motor neurons die, muscles atrophy and weaken. Eventually, patients can no longer walk, talk or breath. ALS is currently diagnosed through multiple tests, with no definitive diagnostic. With a single strand of hair, LinusBio’s diagnostic platform can vastly accelerate and simplify the diagnostic process.

Status: Enrollment ongoing

IBS and eosinophilic esophagitis are chronic and painful conditions often caused by a person’s interactions with their environment. Exposomic readouts can help delineate underlying causes, providing a clinical strategy to help control these conditions.

Status: Enrollment ongoing

Cancers respond best to treatment when they are detected early and that is particularly true for pediatric tumors. Exposomic data identifies the body’s response to malignancies, providing a roadmap for further care.

Status: 1K complete, growing to 100K

Just like genomic information, which grows increasingly valuable as more gene variations and regulatory features are discovered, exposomic data gains value as it matures. LinusBio’s growing exposomic dataset is helping us develop a biomarker-based platform for multiple applications. 
In addition, biopharma companies can use this dataset to optimize clinical trial recruitment, set objective study endpoints, open new windows into patient compliance and drug pharmacology and solve many other problems.

Status: Prototype complete for total analysis

People are often exposed to heavy metals, noxious gases and other toxins – both out in the world and in their own homes. LinusBio’s exposomic platform reads the body’s metabolic responses to these exposures, providing insights that could inform remediation, detoxification and other measures.